New Antimicrobial Agents for the Treatment of Staphylococcal Infections in Children.

Citation data:

Pediatric clinics of North America, ISSN: 1557-8240, Vol: 64, Issue: 6, Page: 1369-1387

Publication Year:
2017
Usage 3
Abstract Views 2
Link-outs 1
Captures 11
Readers 11
Social Media 5
Tweets 5
Citations 3
Citation Indexes 3
Repository URL:
https://touroscholar.touro.edu/tcopny_pubs/143
PMID:
29173791
DOI:
10.1016/j.pcl.2017.08.005
Author(s):
Sharma, Roopali; Francois, Densley; Hammerschlag, Margaret R.
Publisher(s):
Elsevier BV; W.B. Saunders; Touro Scholar
Tags:
Medicine; Anti-Infective Agents; Child; Humans; Staphylococcal Infections; Staphylococcus aureus; Bacterial Infections and Mycoses; Chemicals and Drugs
Most Recent Tweet View All Tweets
review description
Several new antimicrobial agents-daptomycin, ceftaroline, telavancin, dalbavancin, and-tedizolid have been approved for the treatment of staphylococcal infections, including methicillin-resistant Staphylococcus aureus (MRSA), in adults. Ceftaroline and daptomycin have been approved by the US Food and Drug Administration for use in children. Ceftaroline, a beta-lactam antibiotic with activity against MRSA, has been approved for treatment of community-acquired bacterial pneumonia and complicated skin and skin structure infections. Daptomycin has been approved for treatment of complicated skin and skin structure infections. In this article, we review the pharmacokinetics and pharmacodynamics of these antibiotics and available data on use in children.